gdc
Bladder Cancer

Drugs for Bladder Cancer

Here are the financial support services available to patients receiving treatment for Bladder Cancer.

Bavencio (avelumab)

Drug company: EMD Serono/Pfizer
844-826-8371

Bavencio is a PD-L1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-­containing chemotherapy.

EMD Serono and Pfizer offer 2 financial assistance programs for patients using Bavencio:

CoverOne Co-Pay Assistance Program

Through this program, patients with private insurance will be responsible for a $0 copay for Bavencio at participating medical facilities and pharmacies, and may be eligible for copay assistance up to a maximum of $30,000 annually.

CoverOne Patient Assistance Program

This program provides Bavencio at no charge for patients who meet certain income, insurance, and residency eligibility criteria.

Imfinzi (durvalumab)

Drug company: AstraZeneca
844-275-2360

Imfinzi is a PD-L1 inhibitor used to treat patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-­containing chemotherapy or within 12 months of neo­adjuvant or adjuvant treatment with platinum-containing chemotherapy.

AstraZeneca Access 360 offers 2 financial assistance programs for patients using Imfinzi:

Access 360 Imfinzi Patient Savings Program

Patients with private insurance will pay $0 per infusion of Imfinzi; this program pays the remaining out-of-pocket costs up to a maximum of $26,000 annually, with a program ­maximum of $100 per infusion assistance. Residents of Massachusetts, Michigan, Minnesota, and Rhode Island are not eligible for this assistance.

AZ&Me Prescription Savings Program

This prescription savings program offers free, mail-based medication to qualifying patients who have no insurance, those who have Medicare Part D coverage, and some patients with Medicare Part B coverage. General eligibility requirements include limited household income and/or a life-changing event in the past year that affected the patient’s finances. Patients with Medicare Part D coverage must spend 3% of their total household income on prescription medicines through a Medicare Part D prescription plan during the current calendar year, and must be unable to enroll in Medicare Limited Income Subsidy.

Patients with Medicare Part B coverage should call 800-292-6363 for program requirements. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of the medication (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) who are not eligible for cisplatin-­containing chemotherapy, or whose disease has progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with ­platinum-containing chemotherapy.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income level up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $60,700 or less for individuals, $82,300 or less for a couple, or $125,500 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Opdivo (nivolumab)

Drug company: Bristol-Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Bristol-Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductibles, copay, or coinsurance costs for eligible patients with private insurance who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol-Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $36,420 for an individual or $49,380 for a family of 2.

Tecentriq (atezolizumab)

Drug company: Genentech
866-422-2377

Tecentriq is a PD-L1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) who are not eligible for cisplatin-­containing chemotherapy and whose tumors express PD-L1, as determined by an FDA-approved test; for patients who are not eligible for any platinum-­containing therapy, regardless of PD-L1 status.

Genentech offers 2 financial assistance programs for pa­tients using Tecentriq:

Genentech BioOncology Co-pay Card

This program has no income requirements for participation. Patients who qualify for this program have a copay of $5. Genentech covers up to $25,000 annually per patient for Tecentriq.

Genentech Patient Foundation

This foundation provides Tecentriq free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Tecentriq is also provided free of charge for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 ­people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.

Drugs Prescribed for Bladder Cancer (Urothelial Carcinoma)

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Bavencio (avelumab)
  • Drug company
  • EMD Serono/Pfizer
  • Indication
  • Locally advanced or metastatic bladder cancer (urothelial carcinoma) that progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy
  • Patient support services
  • CoverOne Co-Pay Assistance Program
    844-826-8371

    CoverOne Patient Assistance Program
    844-826-8371

    Drug name (generic name)
  • Imfinzi (durvalumab)
  • Drug company
  • AstraZeneca
  • Indication
  • Locally advanced or metastatic bladder cancer (urothelial carcinoma) that progressed during or after platinum-based chemo­­therapy or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy
  • Patient support services
  • Access 360 Imfinzi Patient Savings Program
    844-275-2360

    AZ&Me Prescription Savings Program
    800-292-6363

    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Locally advanced or metastatic bladder cancer (urothelial carcinoma) for patients who are not eligible for cisplatin-containing therapy and whose tumors express PD-L1, as determined by an FDA-approved test

    For patients who are not eligible for any platinum-­containing chemo­therapy, regardless of PD-L1 status
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932


    Drug name (generic name)
  • Tecentriq (atezolizumab)
  • Drug company
  • Genentech
  • Indication
  • Locally advanced or metastatic bladder cancer (urothelial carcinoma) in patients who are not eligible for cisplatin-containing therapy, and whose tumors express PD-L1, as determined by an FDA-approved test

    For patients who are not eligible for any platinum-­containing chemotherapy, regardless of PD-L1 status
  • Patient support services
  • Genentech BioOncology Co-pay Card
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

Last modified: February 11, 2019

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country